Previsioni

Il prezzo obiettivo medio degli analisti è +4,29€ (+254,55%). La mediana è +4,29€ (+254,55%).

Acquista	5
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Ocugen unveils late-stage gene therapy strategy for eye diseases

Ocugen presented a late-stage gene therapy strategy at the Canaccord Growth Conference with three programs targeting retinitis pigmentosa (OCU400), Stargardt disease and geographic atrophy (OCU410). A $130 million convertible note is intended to fund the company through 2028 and cover key clinical and regulatory milestones. The company reports solid safety data in more than 325 treated patients, with no therapy-related serious adverse events. Top-line data for OCU400 are expected in Q1 2025 and for OCU410 in Stargardt in Q2 2025; two BLA filings are planned for 2025, and approval for geographic atrophy is targeted for 2028. Ocugen is exploring partnerships outside the U.S. to commercialize and minimize dilutive financing. » Altro su de.investing.com
Ocugen receives FDA RMAT designation for gene therapy OCU410 for geographic atrophy

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Ocugen’s gene therapy candidate OCU410 based on Phase 2 data on efficacy and safety without serious drug‑related adverse events. OCU410 is a one‑time subretinal AAV5‑based therapy delivering RORA and is being developed to treat geographic atrophy due to dry age‑related macular degeneration. Ocugen expects to start the pivotal Phase 3 trial in Q3 2026 and plans to submit a Biologics License Application in 2028; the RMAT designation enables more intensive FDA interaction, a rolling‑BLA and potential accelerated review pathways. » Altro su de.investing.com
Ocugen closes exclusive term sheet for gene therapy OCU400 in MENA region

Ocugen signs a binding term sheet with Roots Pharmaceutical and Al-Dhow for exclusive rights to the gene therapy OCU400 in the MENA region. The company expects upfront and near-term milestone payments of up to USD 4 million, sales-related milestones of up to USD 255 million, and a 22% royalty on net sales; Ocugen is to handle commercial manufacturing. OCU400 is in the liMeliGhT phase-3 study; topline data are expected in Q1 2027, followed by a planned BLA submission. Ocugen has a market capitalization of USD 497.63 million, 12-month revenue of USD 4.46 million and EPS of -USD 0.23; InvestingPro currently rates the stock as undervalued. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Ocugen ha registrato ricavi pari a 1,30M€ e un utile netto di −21,80M€

(EUR)	giu 2026	YoY
Ricavi	+1,30M	11,93%
Utile lordo	+1,30M	11,93%
Utile netto	−21,80M	74,31%
EBITDA	−17,36M	60,45%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+410,71M€
Numero di azioni	339,11M
Massimo/minimo a 52 settimane	+2,34€ - +0,86€
Dividendi	No
Beta	2,2
Rapporto P/E	−5,58
Rapporto PEG	+0,26
Rapporto P/B	−28,84
Rapporto P/S	+104,40

Profilo aziendale

Ocugen, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung von Gentherapien zur Heilung von Erblindungskrankheiten konzentriert. Die Produktpipeline des Unternehmens umfasst OCU400, einen neuartigen Gentherapieproduktkandidaten zur Wiederherstellung der Netzhautintegrität und -funktion bei einer Reihe genetisch unterschiedlicher erblicher Netzhauterkrankungen wie Retinitis pigmentosa und kongenitaler Leber-Amaurose; OCU410, einen Gentherapiekandidaten zur Behandlung der trockenen altersbedingten Makuladegeneration (AMD); und OCU200, ein neuartiges Fusionsprotein, das sich in der präklinischen Entwicklungsphase für die Behandlung des diabetischen Makulaödems, der diabetischen Retinopathie und der feuchten AMD befindet. Ocugen, Inc. hat eine strategische Partnerschaft mit CanSino Biologics Inc. für die gemeinsame Entwicklung und Herstellung von Gentherapien und mit Bharat Biotech für die Vermarktung von COVAXIN auf dem US-amerikanischen Markt. Der Hauptsitz des Unternehmens befindet sich in Malvern, Pennsylvania.

Nome	Ocugen
CEO	Shankar Musunuri
Sede centrale	Malvern, pa Stati Uniti
Sito web	ocugen.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	03/12/2014
Dipendenti	116